McCarthy Commends FDA’s Decision to Hold Public Valley Fever Workshop
Today, Congressman Kevin McCarthy released the following statement after the Food and Drug Administration (FDA) announced it will hold a public Valley Fever workshop on May 8, 2020. Last month, McCarthy sent a letter to the FDA requesting the agency hold public workshops to help with Valley fever drug and vaccine development.
“The FDA’s announcement is welcome news – this workshop will serve as an important opportunity to gather experts in order to increase collaboration on this neglected disease,” said McCarthy. “This forum will be an excellent springboard for continued discussions on Valley Fever diagnostic and vaccine development, as well as clinical trial designs for antifungal treatments. I highly encourage those who are interested in attending the workshop to sign-up on the FDA’s website.”
- The FDA routinely holds public workshops that bring together researchers, drug developers and government officials to discuss best practices for getting drugs or vaccines approved for specific diseases.
- These public workshops can help inform FDA’s Guidance for Industry documents, which contain non-binding recommendations to help drug developers secure FDA approval for their treatments.
- Section 4 of Congressmen McCarthy and Schweikert’s bill, the FORWARD Act (H.R. 2858), would direct the FDA to hold public workshops on Valley Fever drug and vaccine development and issue a Guidance for Industry document to help with the development of such treatments.